RxDoctor Payments Data

Glen Hyde, MD

Internal Medicine · Yukon, OKNPI 1912907056

Payments from drug & device makers

$1,531in general payments, 2019–2025

Across 95 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$449
  • Pfizer$323
  • Astellas Pharma US Inc$211
  • Lilly USA, LLC$118
  • AstraZeneca$106
  • Merck$74
  • plus $250 from 11 others

What the payments were for

  • Food & beverage$1,46696%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,531 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$184,603
Medicare patients
479
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$143,611
OzempicSemaglutide139$140,585
JardianceEmpagliflozin91$82,122
TrulicityDulaglutide48$72,542
MounjaroTirzepatide62$66,296
JanuviaSitagliptin Phosphate38$33,565
InvokanaCanagliflozin16$27,464
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$21,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,582
MyrbetriqMirabegron39$17,780
XareltoRivaroxaban18$15,358
RybelsusSemaglutide12$14,290
FarxigaDapagliflozin Propanediol17$14,058
Breo ElliptaFluticasone/Vilanterol26$12,579
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$10,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$67$154,874151 claims
PfizerEliquis$323$143,611161 claims
Lilly USA, LLCTrulicity, Mounjaro$118$138,837110 claims
MerckJanuvia$74$33,56538 claims
AstraZenecaFarxiga, Symbicort$106$24,07043 claims
Astellas Pharma US IncMyrbetriq$211$17,78039 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$18$6,14713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →